News
![5 High-Yielding Dividend Stocks That Are Bargain Buys: https://g.foolcdn.com/editorial/images/737484/businessman-showing-chart-to-co-worker.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM05BYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d2e6979655a7d575aca390f414486770b01506ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessman-showing-chart-to-co-worker.jpg?locale=us)
5 High-Yielding Dividend Stocks That Are Bargain Buys
If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking. The tech sector has been attracting more attention of late due to the hype around artificial
![This 1 Problem Could Sink at Least 4 Gene-Editing Stocks: https://g.foolcdn.com/editorial/images/737749/3-worried-investors-talk-at-a-table.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTFBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cdee193466bdf48ee746cce606db8bd1adf4d44f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/3-worried-investors-talk-at-a-table.jpg?locale=us)
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
What do CRISPR Therapeutics (NASDAQ: CRSP), Bluebird Bio (NASDAQ: BLUE), Editas Medicine (NASDAQ: EDIT), and Intellia Therapeutics (NASDAQ: NTLA) all have in common? If you said, "They're biotechs
![Better Buy: Nano-X Imaging vs. Viking Therapeutics: https://g.foolcdn.com/editorial/images/736872/a-group-of-scientists-looking-at-a-report.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWxBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2a2328041b472f035cf71ceabd9a6d05623e1eec/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-group-of-scientists-looking-at-a-report.jpg?locale=us)
Better Buy: Nano-X Imaging vs. Viking Therapeutics
Viking Therapeutics (NASDAQ: VKTX) and Nano-X Imaging (NASDAQ: NNOX) are two small-cap healthcare companies with lots of potential, but their shares come with some hefty risks. They've also both
![2 Unstoppable Growth Stocks to Buy in 2023 and Beyond: https://g.foolcdn.com/editorial/images/737604/scientist-looking-through-microscope-2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTFBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--540fb4b846c1fe14d13b3e4bf9cdbd0de64d4616/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-looking-through-microscope-2.jpg?locale=us)
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.
![Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks: https://g.foolcdn.com/editorial/images/737483/a-person-holding-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOGMvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1e757d2f232e521ffadfb5d32db5c8e187d698ab/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-holding-money.jpg?locale=us)
Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks
Whether you're saving for retirement, want to set aside money for travel, or just want to give yourself a raise, dividend stocks can help give you some extra income to accomplish those goals. Plus
![EQS-News: Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
EQS-News: Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
![Why Catalent Stock Flopped Today: https://g.foolcdn.com/editorial/images/737986/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzgvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--095c0d5f216e265ad82d1f55bf7c404ada2643a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg?locale=us)
Why Catalent Stock Flopped Today
It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA).
According to a media report from a leading financial news
![Why Shares of Axsome Therapeutics Fell Wednesday: https://g.foolcdn.com/editorial/images/737958/doctors-white-coat-healthcare-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMjAvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3fb0e695d86212aadd2116297c667417bc7da84d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctors-white-coat-healthcare-1.jpg?locale=us)
Why Shares of Axsome Therapeutics Fell Wednesday
Shares of Axsome Therapeutics (NASDAQ: AXSM) were down more than 10% as of 3:45 p.m. ET Wednesday after the company announced it is offering 3 million shares at $75 each in a stock sale worth $225
![Better Artificial Intelligence Stock: GSK or Eli Lilly?: https://g.foolcdn.com/editorial/images/737932/ai-healthcare.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHcvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9d9e5ff24a14e1c059f5af0b31da6a8c4d01cbc9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ai-healthcare.jpg?locale=us)
Better Artificial Intelligence Stock: GSK or Eli Lilly?
Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of
![Will AT&T Be a Trillion-Dollar Stock by 2050?: https://g.foolcdn.com/editorial/images/737851/att_retail_chicago.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEkvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4800d48d635e23f7c46a20f00827198edafd2861/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att_retail_chicago.jpg?locale=us)
Will AT&T Be a Trillion-Dollar Stock by 2050?
AT&T (NYSE: T) is one of the largest telecom companies in the United States, but it only has a market cap of about $110 billion. That makes it much smaller than the tech titans that have entered the
![As the Bull Roars, Shareholders Hate How These 2 Companies Are Selling Their Stock: https://g.foolcdn.com/editorial/images/737871/space-getty-star-rising-2018_05_10-12_39_51-utc.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3MrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4f07090e0940c35234aee12399a009e2bf1d4e5b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/space-getty-star-rising-2018_05_10-12_39_51-utc.jpg?locale=us)
As the Bull Roars, Shareholders Hate How These 2 Companies Are Selling Their Stock
The stock market has treated investors well so far in 2023, and although the past couple of weeks have been a bit more turbulent, the Nasdaq Composite (NASDAQINDEX: ^IXIC) gave Wall Street a gain of
![What Will AbbVie Buy Next?: https://g.foolcdn.com/editorial/images/737846/ma.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNncrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c9ec8b747412c3eecfd9b65ecb8f51e76ccfc1cf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ma.jpg?locale=us)
What Will AbbVie Buy Next?
AbbVie (NYSE: ABBV) is facing a tough year ahead. The company's blockbuster drug Humira, which treats various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, will
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![2 Under-the-Radar Biotech Stocks to Buy in 2023: https://g.foolcdn.com/editorial/images/737101/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMncrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--194984d9fd0fc2a983ff7f1bed93eb46c130c08d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
2 Under-the-Radar Biotech Stocks to Buy in 2023
There are plenty of well-known biotech giants that look like solid investments. But targeting smaller and relatively unknown companies in the industry could provide much juicier returns over the
![Why Viking Therapeutics Is Plunging Today: https://g.foolcdn.com/editorial/images/737709/downward-trend.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFk5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--16074c0401c49204f5e9e9392a16b3b8a77c1764/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/downward-trend.jpg?locale=us)
Why Viking Therapeutics Is Plunging Today
Clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume
![Snowflake and Nvidia Partner to Create an Unstoppable AI Superteam: https://g.foolcdn.com/editorial/images/737718/snowflake-nvidia-ai.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOGc5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--61ee53ebe5d0269e26992f1258debb67e7e9fabd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/snowflake-nvidia-ai.jpg?locale=us)
Snowflake and Nvidia Partner to Create an Unstoppable AI Superteam
On Monday, Snowflake (NYSE: SNOW) and Nvidia (NASDAQ: NVDA) announced a partnership at the Snowflake Summit 2023. "Snowflake's partnership with NVIDIA will bring high-performance machine learning
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
![Why Viking Therapeutics Stock Is Crashing Today: https://g.foolcdn.com/assets/images/fool/tmf-logo_400x400.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaTRFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--7b1053a3605f66e35a9c178293b2594f08cb4204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tmf-logo_400x400.png?locale=us)
Why Viking Therapeutics Stock Is Crashing Today
Viking Therapeutics' (NASDAQ: VKTX) shares were down by 9.9% on heavy volume as of 11:14 a.m. ET on Monday. This sizable drop was due to Pfizer's (NYSE: PFE) announcement that it will advance its
![Why Shares of Structure Therapeutics Rose Monday: https://g.foolcdn.com/editorial/images/737621/scientists-examine-cell-make-up-microscope-biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGs4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c35c0b48eb5ce2b1a365e9b66f6a5e7aaa707ea7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-examine-cell-make-up-microscope-biotech.jpg?locale=us)
Why Shares of Structure Therapeutics Rose Monday
Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The
![Why Amgen Stock Slumped on Monday: https://g.foolcdn.com/editorial/images/737620/person-in-a-lab-looking-through-a-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMjQ4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--97a5aff419f83e16ab40ffecce642d3573504af7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-in-a-lab-looking-through-a-microscope.jpg?locale=us)
Why Amgen Stock Slumped on Monday
Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a
![Why Pfizer Stock Is Tanking Today: https://g.foolcdn.com/editorial/images/737548/weight-loss-pills.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeDg4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76f7fd3660bee75637ac2cceca9e97e97924da5b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/weight-loss-pills.jpg?locale=us)
Why Pfizer Stock Is Tanking Today
Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning.
The big dip came
![2 Low-Priced Stocks That Could Make You Richer: https://g.foolcdn.com/editorial/images/737536/thumbnail_oral-medications.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1k4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bb7c045b508dde7728bafcd0643131829846e9ab/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/thumbnail_oral-medications.jpg?locale=us)
2 Low-Priced Stocks That Could Make You Richer
Buying low-priced growth stocks ($10 or below) can be risky. Companies with bargain-basement share prices tend to have weak balance sheets, highly uncertain outlooks, and limited financing
![Is GSK a Strong Buy Right Now?: https://g.foolcdn.com/editorial/images/737534/pills-dollar-symbol.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1U3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ceb256f94f556c1a21169af5103355f6c80b5c59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pills-dollar-symbol.jpg?locale=us)
Is GSK a Strong Buy Right Now?
Dividend-paying pharmaceutical stocks have an outstanding track record of producing market-beating returns on capital. The core reason is that major drug manufacturers tend to generate enormous free
![Better Recovery-Story Buy: Emergent BioSolutions or Invitae?: https://g.foolcdn.com/editorial/images/737334/gettyimages-1147525564.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDg3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b43c5fb06aae7e523b7f7395f013f0cc448010b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1147525564.jpg?locale=us)
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)